AU2020901760A0 - Nanoparticle conjugates and their use in therapeutic applications - Google Patents

Nanoparticle conjugates and their use in therapeutic applications

Info

Publication number
AU2020901760A0
AU2020901760A0 AU2020901760A AU2020901760A AU2020901760A0 AU 2020901760 A0 AU2020901760 A0 AU 2020901760A0 AU 2020901760 A AU2020901760 A AU 2020901760A AU 2020901760 A AU2020901760 A AU 2020901760A AU 2020901760 A0 AU2020901760 A0 AU 2020901760A0
Authority
AU
Australia
Prior art keywords
therapeutic applications
nanoparticle conjugates
nanoparticle
conjugates
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020901760A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sydney
Original Assignee
University of Sydney
Filing date
Publication date
Application filed by University of Sydney filed Critical University of Sydney
Publication of AU2020901760A0 publication Critical patent/AU2020901760A0/en
Abandoned legal-status Critical Current

Links

AU2020901760A 2020-05-29 Nanoparticle conjugates and their use in therapeutic applications Abandoned AU2020901760A0 (en)

Publications (1)

Publication Number Publication Date
AU2020901760A0 true AU2020901760A0 (en) 2020-06-18

Family

ID=

Similar Documents

Publication Publication Date Title
EP3981434A4 (en) Anti-b7-h4 antibody-drug conjugate and medicinal use thereof
NZ748314A (en) Anti-cmet antibody drug conjugates and methods for their use
EP3684353A4 (en) Topical formulations of cannabinoids and use thereof in the treatment of pain
EP3668972B8 (en) Engineered dnase enzymes and use in therapy
EP3334462B8 (en) Covalent linkers in antibody-drug conjugates and methods of making and using the same
EP2013016B8 (en) Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
EP3703757A4 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP3762032A4 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP4149470A4 (en) Pharmaceutical formulations and uses thereof
AU2022299173A1 (en) Novel therapeutic delivery moieties and uses thereof
EP4137491A4 (en) Imidazolinone derivative and use thereof in medicine
AU2022205057A9 (en) B7h4-targeted antibody-drug conjugates and methods of use thereof
EP3836950A4 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP4074345A4 (en) Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
EP4215208A4 (en) Pharmaceutical combination and use thereof
IL299254A (en) Tubulysins and protein-tubulysin conjugates
AU2020901760A0 (en) Nanoparticle conjugates and their use in therapeutic applications
AU2022213743A9 (en) Conjugate and use thereof
IL309249A (en) Conjugates comprising phosphoantigens and their use in therapy
EP4129283A4 (en) Pharmaceutical combination and use thereof
GB202014736D0 (en) Novel compounds and their use in therapy
AU2020903727A0 (en) Conjugates and their use in therapy
EP3995498A4 (en) Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
IL299334A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP3753579A4 (en) Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy